Presented at the American Academy of Neurology Virtual Annual Meeting, April 17-22, 2021

The VRFCAT-SL was administered to a sample of 29 patients with Parkinson’s disease during clinical neuropsychological evaluation. Based on the analysis presented in this poster, the VRFCAT-SL appears to provide a useful measure of cognitive functional capacity that is not confounded by Parkinson’s disease motor symptoms. Completion time of the VRFCAT-SL is associated with visual memory, sustained attention, and set-switching.

View Poster